PMID- 14630683
OWN - NLM
STAT- MEDLINE
DCOM- 20040427
LR  - 20200203
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 14
IP  - 12
DP  - 2003 Dec
TI  - High-dose chemotherapy and autologous stem cell transplantation in peripheral 
      T-cell lymphoma: the GEL-TAMO experience.
PG  - 1768-75
AB  - BACKGROUND: T-cell immunophenotype constitutes an unfavorable prognostic factor 
      in aggressive non-Hodgkin's lymphomas. High-dose chemotherapy with autologous 
      stem-cell rescue (HDC/ASCT) is the best salvage therapy for patients with 
      aggressive B-cell lymphomas. However, results with this therapy in peripheral 
      T-cell lymphoma (PTCL) are not well defined. PATIENTS AND METHODS: From January 
      1990 to December 1999, 115 patients with PTCL underwent HDC/ASCT inside the Grupo 
      Espanol de Linfomas/Trasplante Autologo de Medula Osea (GEL-TAMO) registry. At 
      diagnosis the median age was 41 years and 60% of patients presented with two or 
      three risk factors from the adjusted International Prognostic Index (a-IPI). 
      Thirty-two per cent of patients were transplanted in first complete response 
      (CR), 62% in chemosensitive disease and 5% in refractory disease. RESULTS: 
      Eighty-six per cent of the patients attained a CR and 5% a partial response (PR). 
      With a median follow-up of 37 months (range 1-133), overall survival (OS), 
      time-to-treatment failure (TTF) and disease-free survival (DFS) at 5 years was 
      56%, 51% and 60%, respectively; for the 37 patients transplanted in first CR, OS 
      and DFS at 5 years were 80% and 79%, respectively. Lactase dehydrogenase (LDH), 
      a-IPI and disease status pre-transplant were associated with outcome. 
      CONCLUSIONS: More than half of patients with chemosensitive disease who were 
      transplanted are expected to be alive at 5 years. We confirm the utility of the 
      pre-transplant IPI system in predicting outcome. Salvage treatment results with 
      HDC/ASCT in PTCL are similar to those found in corresponding aggressive B-cell 
      lymphomas.
FAU - Rodriguez, J
AU  - Rodriguez J
AD  - Hospital Son Dureta, Palma de Mallorca, Spain. jrodriguez@hsd.es
FAU - Caballero, M D
AU  - Caballero MD
FAU - Gutierrez, A
AU  - Gutierrez A
FAU - Marin, J
AU  - Marin J
FAU - Lahuerta, J J
AU  - Lahuerta JJ
FAU - Sureda, A
AU  - Sureda A
FAU - Carreras, E
AU  - Carreras E
FAU - Leon, A
AU  - Leon A
FAU - Arranz, R
AU  - Arranz R
FAU - Fernandez de Sevilla, A
AU  - Fernandez de Sevilla A
FAU - Zuazu, J
AU  - Zuazu J
FAU - Garcia-Larana, J
AU  - Garcia-Larana J
FAU - Rifon, J
AU  - Rifon J
FAU - Varela, R
AU  - Varela R
FAU - Gandarillas, M
AU  - Gandarillas M
FAU - SanMiguel, J
AU  - SanMiguel J
FAU - Conde, E
AU  - Conde E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 04079A1RDZ (Cytarabine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - Q41OR9510P (Melphalan)
RN  - U68WG3173Y (Carmustine)
RN  - BEAM regimen
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use
MH  - Carmustine/administration & dosage
MH  - Cytarabine/administration & dosage
MH  - Disease-Free Survival
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Humans
MH  - Lymphoma, T-Cell, Peripheral/*drug therapy
MH  - Male
MH  - Melphalan/administration & dosage
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - *Peripheral Blood Stem Cell Transplantation
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Salvage Therapy
MH  - Transplantation, Autologous
MH  - Treatment Outcome
MH  - Whole-Body Irradiation
EDAT- 2003/11/25 05:00
MHDA- 2004/04/28 05:00
CRDT- 2003/11/25 05:00
PHST- 2003/11/25 05:00 [pubmed]
PHST- 2004/04/28 05:00 [medline]
PHST- 2003/11/25 05:00 [entrez]
AID - S0923-7534(19)64237-7 [pii]
AID - 10.1093/annonc/mdg459 [doi]
PST - ppublish
SO  - Ann Oncol. 2003 Dec;14(12):1768-75. doi: 10.1093/annonc/mdg459.